Das Klinikum

Univ.-Prof. Dr. med. Christian Schürch, MD, PhD

Univ.-Prof. Dr. med. Christian Schürch, MD, PhD

Bereichsleitender Oberarzt

W3-Professur für Advanced Tissue Imaging und Digitale Pathologie

Kontakt

Telefonnummer: Sekretariat: 07071 29-80201

Telefonnummer: Fax: 07071 29-2991

E-Mail-Adresse: christian.schuerch@med.uni-tuebingen.de

  • Hämatopathologie
  • Gastrointestinale Pathologie
  • Uropathologie
  • Gynäkopathologie
  • Digitale Pathologie
  • Drivers and Brakes of CAR T Cell Efficacy Determined by the Tumor Immune Microenvironment (CAR-TIME)

    ERC Starting Grant

    Cancer immunotherapies with chimeric antigen receptor (CAR) T cells have shown dramatic clinical efficacy in patients with B cell neoplasms. Thus, their clinical use is expected to increase considerably in the near future. However, for poorly understood reasons, not all patients with lymphoma benefit from these expensive therapies. The ability to stratify patients into probable responders vs. non-responders prior to immunotherapy will improve treatment efficacy, limit patient exposure to adverse effects, and mitigate the significant economic costs associated with these therapies.
    We and others have previously demonstrated that effective antitumoral immunity requires complex, spatially coordinated interactions between different cellular elements within the tumor immune microenvironment (TIME). There is evidence that patient response to immunotherapy is attributed to specific characteristics of the TIME, such as the composition, spatial arrangement, and activation states of immune cell types in it. Therefore, a better understanding of the TIME, and of how immunotherapies come into effect in live, intact human tissues, is critical for the selection of successful immunotherapies for our patients.
    The overarching aim of the CAR-TIME project is to explore and visualize the cellular and molecular mechanisms of CAR T cell efficacy in lymphoma, determined by CAR T cell interactions with the TIME. This shall be achieved by creating a high-dimensional map of the TIME of diffuse large B cell lymphoma, performing live tissue cultures treated with immunotherapies, and establishing a novel live cell microscopy platform to interrogate intact human lymphoma tissue treated with CAR T cells. Drug perturbations, multidimensional imaging technologies, RNA sequencing and integrative bioinformatics analysis will illuminate mechanisms of therapy response vs. resistance, reveal novel predictive biomarkers, and inform future combination immunotherapy strategies to improve patient outcomes.

    Laufzeit: 2024-2028

  • 2024 -
    Vizepräsident und Schatzmeister, European Society for Spatial Biology e.V. (ESSB)
  • 2023 -2025
    Weiterbildung Master of Health Business Administration, FAU Erlangen-Nürnberg
  • 2021 -
    W3 Professor und Bereichsleitender Oberarzt, Institut für Pathologie, Universitätsklinikum Tübingen
  • 2020 - 2021
    W3 Professurvertreter und Oberarzt, Institut für Pathologie, Universitätsklinikum Tübingen
  • 2018
    Habilitation im Fach Pathologie, Universität Bern
  • 2017 - 2020
    Postdoc, Baxter Laboratory, Department of Microbiology & Immunology, Stanford University
  • 2017 - 2017
    Stv. Oberarzt, Institut für Pathologie, Universität Bern
  • 2017
    Schweizerischer Facharzttitel für Pathologie
  • 2016 - 2017
    Assistenzarzt, Institut für Pathologie, Universität Bern
  • 2015 - 2016
    Assistenzarzt, Institut für Pathologie, Universitätsklinikum Tübingen
  • 2012 - 2015
    Assistenzarzt, Institut für Pathologie, Universität Bern
  • 2010 - 2012
    Zertifikat (CAS) Hochschuldidaktik, Universität Bern
  • 2008 - 2011
    Promotion MD, PhD, Departement für Biomedizinische Forschung, Universität Bern
  • 2004 - 2007
    Promotion Dr. med., Institut für Infektionskrankheiten, Universität Bern
  • 2001 - 2007
    Medizinstudium, Universität Bern
  • Pathologie der Zelle
  • Herz-Kreislaufpathologie
  • Advanced Oncology